NCT02817789View on ClinicalTrials.gov

Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions

Aortic Valve Stenosis

Interventions

DRUG

Ticagrelor alone

180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure

DRUG

Combination lysine acetylsalicylate - clopidogrel

75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure

Trial Locations (5)

13005

APHM, Marseille

30029

CHRU de Nîmes, Nîmes

33604

CHU de Bordeaux, Pessac

59037

CHRU de Lille, Lille

75013

APHP, Paris

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT02817789 - Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) | Biotech Hunter | Biotech Hunter